Claims Scope:

Patent issued November 25, 2022. 

100% Sequence Identity- Compositions & Methods 

Composition of viral vectors and a pharmaceutical composition for treating condition associated with the mevalonate pathway, encoding shRNA or microRNA inhibiting FDPS comprising shRNA of SEQ 1-4, or microRNA of SEQ 5-10 (100% identity).  

Use of an immunotherapy-based system for treating cancer comprising an envelope protein and a viral vector encoding shRNA or microRNA inhibiting FDPS comprising shRNA of SEQ 1-4, or microRNA of SEQ 5-10 (100% identity)